Trade TFF Pharmaceuticals, Inc. - TFFP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.20 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 3.05 |
| Open* | 3.01 |
| 1-Year Change* | 410.17% |
| Day's Range* | 3.01 - 3.3 |
| 52 wk Range | 4.71-25.75 |
| Average Volume (10 days) | 16.77K |
| Average Volume (3 months) | 378.36K |
| Market Cap | 11.68M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 2.37M |
| Revenue | 932.32K |
| EPS | -16.81 |
| Dividend (Yield %) | N/A |
| Beta | 1.29 |
| Next Earnings Date | Mar 5, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 18, 2024 | 3.05 | -0.18 | -5.57% | 3.23 | 3.32 | 3.05 |
| Apr 17, 2024 | 3.19 | -0.05 | -1.54% | 3.24 | 3.24 | 3.18 |
| Apr 16, 2024 | 3.28 | -0.10 | -2.96% | 3.38 | 3.38 | 3.12 |
| Apr 15, 2024 | 3.47 | -0.51 | -12.81% | 3.98 | 3.98 | 3.42 |
| Apr 12, 2024 | 3.89 | -0.14 | -3.47% | 4.03 | 4.03 | 3.89 |
| Apr 11, 2024 | 3.93 | 0.01 | 0.26% | 3.92 | 3.98 | 3.90 |
| Apr 10, 2024 | 3.93 | -0.27 | -6.43% | 4.20 | 4.35 | 3.83 |
| Apr 9, 2024 | 4.23 | -0.17 | -3.86% | 4.40 | 4.41 | 4.09 |
| Apr 8, 2024 | 4.23 | 0.09 | 2.17% | 4.14 | 4.39 | 4.14 |
| Apr 5, 2024 | 4.38 | -0.15 | -3.31% | 4.53 | 4.53 | 4.28 |
| Apr 4, 2024 | 4.64 | -0.34 | -6.83% | 4.98 | 5.11 | 4.53 |
| Apr 3, 2024 | 4.98 | 0.28 | 5.96% | 4.70 | 5.08 | 4.68 |
| Apr 2, 2024 | 4.82 | -1.16 | -19.40% | 5.98 | 5.98 | 4.81 |
| Apr 1, 2024 | 6.23 | 0.09 | 1.47% | 6.14 | 6.57 | 6.14 |
| Mar 28, 2024 | 6.01 | -0.37 | -5.80% | 6.38 | 6.38 | 5.78 |
| Mar 27, 2024 | 6.38 | 0.05 | 0.79% | 6.33 | 6.66 | 6.00 |
| Mar 26, 2024 | 6.20 | -1.23 | -16.55% | 7.43 | 7.43 | 5.72 |
| Mar 25, 2024 | 7.28 | -0.20 | -2.67% | 7.48 | 7.48 | 7.01 |
| Mar 22, 2024 | 7.49 | -0.41 | -5.19% | 7.90 | 7.98 | 7.23 |
| Mar 21, 2024 | 7.94 | 0.31 | 4.06% | 7.63 | 8.09 | 7.23 |
TFF Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, May 9, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q1 2024 TFF Pharmaceuticals Inc Earnings Release Q1 2024 TFF Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Monday, August 12, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Q2 2024 TFF Pharmaceuticals Inc Earnings Release Q2 2024 TFF Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0.49581 | 0.08816 | 0 | 0 | 0 |
| Total Operating Expense | 32.2926 | 31.8748 | 18.6936 | 11.9876 | 3.89815 |
| Selling/General/Admin. Expenses, Total | 13.7963 | 10.5739 | 8.01209 | 3.16533 | 3.04934 |
| Research & Development | 18.4963 | 21.3009 | 10.6816 | 8.82223 | 0.84881 |
| Operating Income | -31.7968 | -31.7867 | -18.6936 | -11.9876 | -3.89815 |
| Net Income Before Taxes | -31.7701 | -31.0387 | -18.5672 | -11.8702 | -3.84219 |
| Net Income After Taxes | -31.7701 | -31.0387 | -18.5672 | -11.8702 | -3.84219 |
| Net Income Before Extra. Items | -31.7701 | -31.0387 | -18.5672 | -11.8702 | -3.84219 |
| Net Income | -31.7701 | -31.0387 | -18.5672 | -11.8702 | -3.84219 |
| Income Available to Common Excl. Extra. Items | -31.7701 | -31.0387 | -18.5672 | -36.6753 | -4.57054 |
| Income Available to Common Incl. Extra. Items | -31.7701 | -31.0387 | -18.5672 | -36.6753 | -4.57054 |
| Diluted Net Income | -31.7701 | -31.0387 | -18.5672 | -36.6753 | -4.57054 |
| Diluted Weighted Average Shares | 29.9798 | 24.821 | 20.4252 | 18.451 | 17.8254 |
| Diluted EPS Excluding Extraordinary Items | -1.05972 | -1.2505 | -0.90904 | -1.98772 | -0.25641 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -1.05972 | -1.2505 | -0.90904 | -1.98772 | -0.25641 |
| Interest Income (Expense), Net Non-Operating | 0.02673 | 0.05123 | 0.12642 | 0.11733 | 0.05596 |
| Total Adjustments to Net Income | 0 | -24.8051 | -0.72835 | ||
| Revenue | 0.49581 | 0.08816 | |||
| Other, Net | 0 | 0.69671 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.33335 | 0.05143 | 0.31278 | 0.08759 | 0.028 |
| Revenue | 0.33335 | 0.05143 | 0.31278 | 0.08759 | 0.028 |
| Total Operating Expense | 5.35226 | 7.13788 | 7.69356 | 7.36821 | 8.80082 |
| Selling/General/Admin. Expenses, Total | 2.67036 | 3.11922 | 3.55751 | 3.34227 | 3.69001 |
| Research & Development | 2.6819 | 4.01866 | 4.13605 | 4.02594 | 5.11081 |
| Operating Income | -5.01891 | -7.08645 | -7.38078 | -7.28062 | -8.77282 |
| Interest Income (Expense), Net Non-Operating | -0.0013 | 0.03508 | 0.00754 | 0.00612 | 0.00588 |
| Other, Net | 0 | 0 | 0.02061 | ||
| Net Income Before Taxes | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
| Net Income After Taxes | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
| Net Income Before Extra. Items | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
| Net Income | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
| Income Available to Common Excl. Extra. Items | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
| Income Available to Common Incl. Extra. Items | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
| Diluted Net Income | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
| Diluted Weighted Average Shares | 36.1931 | 36.1931 | 29.9798 | 25.4517 | 25.3737 |
| Diluted EPS Excluding Extraordinary Items | -0.13871 | -0.19483 | -0.24594 | -0.28582 | -0.3447 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.13871 | -0.19483 | -0.24594 | -0.28582 | -0.3447 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Liabilities | 1.13066 | 1.96075 | 1.32204 | 0.41064 | 1.157 |
| Accounts Payable | 0.91961 | 1.49384 | 1.29773 | 0.41064 | 0.42865 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.24076 | 1.96075 | 1.32204 | 1.54265 | 1.157 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 22.8795 | 38.7371 | 37.3398 | 27.6448 | 9.24451 |
| Retained Earnings (Accumulated Deficit) | -97.0884 | -65.3184 | -34.2797 | -15.7124 | -3.84219 |
| Total Liabilities & Shareholders’ Equity | 24.1202 | 40.6978 | 38.6618 | 29.1874 | 10.4015 |
| Total Common Shares Outstanding | 36.1931 | 25.3718 | 22.5349 | 18.451 | 17.8254 |
| Total Current Assets | 19.0252 | 38.838 | 37.559 | 29.1874 | 10.2737 |
| Cash and Short Term Investments | 16.6123 | 33.7947 | 35.3008 | 28.0949 | 10.2617 |
| Cash & Equivalents | 16.6123 | 33.7947 | 35.3008 | 28.0949 | 10.2617 |
| Prepaid Expenses | 2.22634 | 2.44793 | 2.25823 | 1.09246 | 0.01207 |
| Total Assets | 24.1202 | 40.6978 | 38.6618 | 29.1874 | 10.4015 |
| Other Long Term Assets, Total | 0.00769 | 0 | 0.12777 | ||
| Accrued Expenses | 0.08506 | 0.41691 | 0 | 0.72835 | |
| Preferred Stock - Non Redeemable, Net | 12.486 | ||||
| Common Stock | 0.03619 | 0.02537 | 0.02254 | 0.01845 | 0.004 |
| Additional Paid-In Capital | 120.071 | 104.079 | 71.6485 | 43.3387 | 0.59672 |
| Other Liabilities, Total | 0.11009 | 0 | 1.13201 | ||
| Redeemable Preferred Stock | 0 | ||||
| Property/Plant/Equipment, Total - Net | 3.27439 | 1.85986 | 1.10281 | ||
| Other Current Liabilities, Total | 0.126 | 0.05 | 0.02432 | ||
| Other Equity, Total | -0.1393 | -0.04892 | -0.05154 | ||
| Total Receivables, Net | 0.18651 | 2.59535 | |||
| Note Receivable - Long Term | 1.81298 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 10.8929 | 9.41557 | 13.9604 | 19.0252 | 16.979 |
| Cash and Short Term Investments | 9.72576 | 7.66297 | 12.2164 | 16.6123 | 13.1471 |
| Cash & Equivalents | 9.72576 | 7.66297 | 12.2164 | 16.6123 | 13.1471 |
| Prepaid Expenses | 0.80566 | 1.46843 | 1.55531 | 2.22634 | 1.06976 |
| Total Assets | 14.8852 | 13.5693 | 18.2117 | 24.1202 | 20.2274 |
| Property/Plant/Equipment, Total - Net | 2.20358 | 2.31605 | 2.40387 | 3.27439 | 3.24073 |
| Total Current Liabilities | 1.14201 | 1.21494 | 1.57684 | 1.13066 | 2.07657 |
| Accounts Payable | 0.98329 | 1.007 | 1.34443 | 0.91961 | 1.63402 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.076 | 0.126 | 0.151 | 0.126 | 0.36271 |
| Total Liabilities | 1.19424 | 1.28727 | 1.66837 | 1.24076 | 2.20489 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 13.6909 | 12.282 | 16.5433 | 22.8795 | 18.0225 |
| Common Stock | 0.05913 | 0.03619 | 0.03619 | 0.03619 | 0.02552 |
| Additional Paid-In Capital | 127.405 | 121.571 | 120.805 | 120.071 | 107.923 |
| Retained Earnings (Accumulated Deficit) | -113.569 | -109.16 | -104.14 | -97.0884 | -89.7152 |
| Other Equity, Total | -0.20371 | -0.16553 | -0.15796 | -0.1393 | -0.21035 |
| Total Liabilities & Shareholders’ Equity | 14.8852 | 13.5693 | 18.2117 | 24.1202 | 20.2274 |
| Total Common Shares Outstanding | 59.1336 | 36.1931 | 36.1931 | 36.1931 | 25.5181 |
| Total Receivables, Net | 0.36149 | 0.28417 | 0.18877 | 0.18651 | 2.76214 |
| Accrued Expenses | 0.08273 | 0.08194 | 0.08141 | 0.08506 | 0.07984 |
| Other Long Term Assets, Total | 0.00769 | 0.00769 | 0.00769 | 0.00769 | 0.00769 |
| Other Liabilities, Total | 0.05223 | 0.07233 | 0.09152 | 0.11009 | 0.12831 |
| Note Receivable - Long Term | 1.781 | 1.83 | 1.83969 | 1.81298 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -31.7701 | -31.0387 | -18.5672 | -11.8702 | -3.84219 |
| Cash From Operating Activities | -27.3422 | -29.557 | -16.6156 | -11.2161 | -2.12699 |
| Changes in Working Capital | -0.55108 | -1.59719 | -0.25982 | 0.06407 | 0.38612 |
| Cash From Investing Activities | -1.55133 | -0.86851 | -1.10281 | 0 | 0 |
| Other Investing Cash Flow Items, Total | 0 | 0 | |||
| Cash From Financing Activities | 11.751 | 28.885 | 24.9947 | 29.0494 | 12.3887 |
| Financing Cash Flow Items | 0 | -0.09731 | |||
| Net Change in Cash | -17.1824 | -1.50613 | 7.20587 | 17.8333 | 10.2617 |
| Non-Cash Items | 4.59076 | 2.96748 | 2.21146 | 0.59004 | 1.32907 |
| Issuance (Retirement) of Stock, Net | 11.751 | 28.885 | 24.9947 | 29.0494 | 12.486 |
| Cash From Operating Activities | 0.38822 | 0.11145 | 0 | ||
| Capital Expenditures | -1.55133 | -0.86851 | -1.10281 | ||
| Foreign Exchange Effects | -0.03987 | 0.03436 | -0.0704 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.05137 | -31.7701 | -24.3968 | -17.1223 | -8.376 |
| Cash From Operating Activities | -4.36578 | -27.3422 | -19.6402 | -12.2607 | -7.2463 |
| Cash From Operating Activities | 0.12317 | 0.38822 | 0.26731 | 0.16617 | 0.07703 |
| Non-Cash Items | 1.44312 | 4.59076 | 2.80813 | 1.87762 | 0.6527 |
| Changes in Working Capital | 1.1193 | -0.55108 | 1.68119 | 2.81779 | 0.39998 |
| Cash From Investing Activities | 0 | -1.55133 | -1.41016 | -0.63268 | -0.13723 |
| Capital Expenditures | 0 | -1.55133 | -1.41016 | -0.63268 | -0.13723 |
| Cash From Financing Activities | -0.01792 | 11.751 | 0.41474 | -0.016 | 0 |
| Issuance (Retirement) of Stock, Net | 11.751 | 0.41474 | 0.01019 | 0 | |
| Foreign Exchange Effects | -0.01225 | -0.03987 | -0.01197 | 0.00501 | 0.00303 |
| Net Change in Cash | -4.39596 | -17.1824 | -20.6476 | -12.9044 | -7.3805 |
| Financing Cash Flow Items | -0.01792 | -0.02618 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
TFF Pharmaceuticals, Inc. Company profile
About TFF Pharmaceuticals Inc
TFF Pharmaceuticals, Inc. is an early stage biopharmaceutical company. The Company is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Voriconazole Inhalation Powder (VIP), TFF Tacrolimus Inhalation Powder (TIP) and Triple Combination. It is developing TFF VIP to treat invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF VIP is being developed as an inhaled dry powder drug. It is developing TFF TIP, a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. It is developing Triple Combination, a dry powder drug combination to treat chronic obstructive pulmonary disease (COPD) and asthma. Its other dry powder products include Inhaled SARS-CoV2 Monoclonal Antibody, Niclosamide Inhalation Powder, Cannabidiol (CBD) and Vaccines.
Financial summary
BRIEF: For the nine months ended 30 September 2021, TFF Pharmaceuticals Inc revenues increased from $0K to $76K. Net loss increased 66% to $21M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $2.8M to $14.1M (expense), Stock-based Compensation in SGA increase of 98% to $2.4M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
2600 Via Fortuna Ste 360
AUSTIN
TEXAS 78746-7983
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com